AbbVie Says Canada's Drug Agency Has Issued Its First-Ever Time-limited Reimbursement Recommendation For EPKINLY (Epcoritamab)
AbbVie Says Canada's Drug Agency Has Issued Its First-Ever Time-limited Reimbursement Recommendation For EPKINLY (Epcoritamab)
艾伯維公司表示，加拿大藥品管理機構首次發佈了關於EPKINLY（Epcoritamab）的有限期付款建議。
This recommendation recognizes the unmet need of adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.
該建議認識到，經過兩條或更多系列全身治療的復發或難治性瀰漫性大B細胞淋巴瘤（R/R DLBCL）的成年患者的需求尚未得到滿足，他們之前接受過或無法接受CAR-T細胞療法。
EPKINLY has also received a positive recommendation for the same indication from INESSS to list it in Quebec contingent on submission and reassessment of phase III clinical data once available.
EPKINLY還收到了INESSS對相同適應症的積極建議，將其在魁北克上市，前提是提交併重新評估了三期臨床數據。
EPKINLY is being co-developed by AbbVie and Genmab as part of their oncology collaboration.
作爲腫瘤學合作的一部分，艾伯維和Genmab正在共同開發EPKINLY。